Efficacy of denosumab against osteoporosis determined using quantitative computed tomography in treatment-naïve male patients with ankylosing spondylitis: case series of six patients

Figures & data

Table 1. Baseline demographics and follow-up bone marrow density (BMD) measured by quantitative computed tomography (qCT).

				Drugs							Baseline DXA			qCT
Patient no.	Age (years)/sex	Disease duration (years)	HLA-B27	GC	Vit D	Ca	PPI	NSAIDs	csDMARDs	bDMARDs, type	BMD (g/cm^2)	Z-score	T-score	Baseline BMD (mg/cm^3)	1 year follow-up (mg/cm^3)	Change 1st year (%)	2 year follow-up (mg/cm^3)	Change 2nd year* (%)
1	45/M	25	+	No	Yes	No	No	No	No	Yes, adalimumab 40 mg biweekly	1.06	−1.6	−1.0	59.93	85.25	+42.3	No treatment	No treatment
2	48/M	18	+	No	No	No	Yes	Yes	No	Yes, etanercept 50 mg weekly	1.15	−0.7	−0.3	49.60	63.68	+28.4	68.73	+7.9
3	45/M	22	+	No	No	No	No	No	No	Yes, adalimumab 40 mg once every 2 weeks	1.44	0.3	2.2	12.48	16.40	+31.5	17.23	+5.0
4	44/M	19	+	Yes	No	No	No	Yes	Yes	No	–	–	–	48.70	63.25	+29.9	62.90	−0.6
5	50/M	23	+	No	No	No	No	Yes	No	No	0.68	−3.1	−4.1	43.20	58.48	+35.4	68.73	+17.5
6	50/M	5	+	No	No	No	No	No	No	No	1.22	1.0	0.4	58.95	60.08	+1.9	72.10	+20.0

HLA, human leucocyte antigen; GC, glucocorticoid; Vit D, vitamin D; Ca, calcium; PPI, proton pump inhibitor; NSAID, non-steroidal anti-inflammatory drug; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; bDMARD, biological disease-modifying anti-rheumatic drug; DXA, dual-energy X-ray absorptiometry; M, male; F, female.

*BMD change from 1 year to 2 year follow-up.